/

Sociétés

AA

Non vérifié

AAVantgarde

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologieFinanceLoi/Droit/FiscalitéMédecine Santé Bien-être

17 communiqués de presse

Voir tous les communiqués de presse

16/09/2026

Biotechnologie

Médecine Santé Bien-être

AAVantgarde to Showcase Clinical Progress in Usher 1B and Stargardt Disease at EURetina 2026

Source

Émetteur

1.00

0

01/09/2026

Biotechnologie

AAVantgarde appoints Megan Zoschg Canniere as Chief Regulatory & Quality Officer

Source

Émetteur

1.00

0

23/07/2026

Biotechnologie

AAVantgarde Announces Participation of Founder and CSO, Prof. Alberto Auricchio at the 32nd Annual Meeting of the Japanese Society for Gene and Cell Therapy

Source

Émetteur

1.00

0

23/04/2026

Biotechnologie

AAVantgarde to Participate in ARVO 2026, with Presentations at Key Pre-events and New Clinical Data from the LUCE Phase 1/2 Study

Source

Émetteur

1.00

0

21/04/2026

Biotechnologie

Annonces Économiques

AAVantgarde announces completion of recruitment in STELLA natural history study

Source

Émetteur

1.00

0

01/04/2026

Biotechnologie

AAVantgarde appoints Philip Lao as Senior Vice President of Business Development

Source

Émetteur

1.00

0

15/01/2026

Biotechnologie

AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa

Source

Émetteur

1.00

0

08/01/2026

Biotechnologie

AAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare Conference

Source

Émetteur

1.00

0

03/11/2025

Biotechnologie

Finance

AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome

Source

Émetteur

1.00

0

07/10/2025

Biotechnologie

AAVantgarde announces 3 presentations at ESGCT 2025 annual meeting

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0